AbbVie's investigational HCV regimen receives FDA Breakthrough Therapy Designation
Enanta announced the FDA has granted Breakthrough Therapy Designation for AbbVie’s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for treatment of patients with chronic HCV who failed previous therapy with DAAs in genotype 1. September 30, 2016